Publications and Presentations

Check out our publications and poster presentations.

September 2022

A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory (R/R) NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)

North America Conference on Lung Cancer

July 2022

Phase 2 Study of the SYK Inhibitor Mivavotinib in Relapsed/Refractory (R/R) NON-GCB Diffuse Large B-cell Lymphoma (DLBCL) With or Without MYD88 and/or CD79 Mutations

Pan Pacific Lymphoma Conference

April 2022

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical Cancer Research

April 2022

Identification of novel VPS4A inhibitors for the treatment of VPS4B-deleted cancers

American Association for Cancer Research

November 2021

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.

PLOS One

Our Pipeline

We are focused on novel treatments for
cancer and other life-threatening diseases.

View Our Pipeline